Low dose GLP-1 for heart health in HIV
Part of Hormones & metabolism clinical trials.
This study tests a very low dose of a medication called a GLP-1 receptor agonist to see if it can improve heart and metabolic health in people with HIV who have excess weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and are on a stable HIV medication regimen.
- Your body mass index (BMI) is 30 or higher, or at least 27 if you have a weight-related condition like high blood pressure or high cholesterol.
- You do not have diabetes or take diabetes medication (except metformin for pre-diabetes).
- You weigh less than 400 pounds.
- You are not planning to start a strict diet, intense exercise, or weight loss drugs during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
This trial tests if a once-weekly diabetes medication (semaglutide) can help people with HIV reduce heavy drinking and improve heart health. It's for people who drink alcohol and have a higher body weight.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests a nasal spray containing semaglutide (a GLP-1 receptor agonist) to see if it helps adults who are overweight or obese lose weight. It may be an option if you have a BMI between 27 and 35 and have not used other weight loss medications recently.
This study tests if a weekly injection (semaglutide) combined with an exercise program can help reduce fat stored in the heart and muscles in people with type 2 diabetes. It may improve how well your body handles sugar and lowers your risk for heart problems.
Hear when a new Weight Gain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.